SCHEMBL26697116

SCHEMBL26697116

CC(C)(C)OC(=O)N(c1ncncn1)C1CCNCC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.34
SLC6A2 P23975 7/20 0.34
SLC6A3 Q01959 6/20 0.34
TACR1 P25103 5/20 0.33
GPR119 Q8TDV5 3/20 0.33
PLAT P00750 1/20 0.32
CYP2D6 P10635 3/20 0.32
CHRM3 P20309 1/20 0.32
KCNH2 Q12809 1/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
EHMT2 Q96KQ7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28329578 0.92 SLC6A4 (0.39) SLC6A4SLC6A2SLC6A3CYP2D6CHRM3
SCHEMBL29017156 0.89 GPR119 (0.38) SLC6A4SLC6A2SLC6A3TACR1GPR119
SCHEMBL2597129 0.83 EP300 (0.34) SLC6A4SLC6A2SLC6A3TACR1PLAT
SCHEMBL529996 0.78 SLC6A4 (0.36) SLC6A4SLC6A2SLC6A3CYP2D6CHRM3
SCHEMBL27884240 0.76 SMN1; SMN2 (0.47) ALDH1A1
SCHEMBL2351678 0.76 TACR1 (0.36) SLC6A4SLC6A2SLC6A3TACR1GPR119
SCHEMBL12469312 0.76 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3TACR1CYP2D6
SCHEMBL30502020 0.75 GPR119 (0.40) SLC6A4SLC6A2SLC6A3TACR1GPR119
SCHEMBL17560116 0.75 TACR1 (0.41) SLC6A4SLC6A2SLC6A3TACR1CYP2D6
SCHEMBL9900211 0.74 TACR1 (0.32) SLC6A4SLC6A2SLC6A3TACR1PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023227125-A1 NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2023-11-30 WO disclosed